Study of Histoglob for chronic hives in real-life care
Part of Immune system & allergy, Skin clinical trials.
This trial is looking at how well the drug Histoglob (Immunoglobulin-Histamine Complex) works for people with chronic urticaria (hives that last a long time). It's for patients who are already on a first-line treatment and are starting Histoglob for the first time as part of their regular care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 13 years or older.
- You have chronic hives (lasts more than 6 weeks) that have been scored before starting this treatment.
- You are already taking a first-line treatment for your hives.
- Your doctor has prescribed Histoglob injections for you for the first time.
- You are not allergic to Histoglob or human immunoglobulin products.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment options for people with chronic hives (urticaria) that have lasted more than 6 weeks. It aims to find which treatment works best and is safe.
This trial tests a new medication called THB335 for people with chronic spontaneous urticaria (CSU), which causes hives and itching for months without a clear cause. The study will see if the drug can reduce hives and itching better than a placebo (a pill with no active medicine).
This trial tests a new medication (HS-10561) first in healthy adults to check safety, then in people with chronic spontaneous urticaria (long-term hives without a known cause) to see if it helps reduce symptoms. It may be an option for those who have had hives for at least 6 months.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
Hear when a new Chronic Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.